Skip to Content
Open menu / Close menu
Annual report 2023
Open submenu
, Annual report 2023
Management review 2023
Meds75+ and the National Risk Medicines Classification are information products offered by Fimea for daily health care
The location of notified bodies in Finland is an advantage for the diagnostics industry
From national to European – veterinary antibiotics consumption monitoring has been effective
All clinical trials now begin in compliance with the EU Regulation
The Benchmarking process of the European Medicines Agency Network inspires improvement through learning from others
Fimea’s reputation with the media has improved
Patient Advisory Board’s work has developed over the years
Fimea develops agile procurement and expertise – adverse drug reactions database was the pilot
Annual report 2022
Open submenu
, Annual report 2022
Management review 2022
Small country, big agency
Fimea active in EU-level development work
A year of many legislative changes for Fimea and operators
Fimea has a strong role in pharmaceutical reform
Fimea continued to promote medication safety and safe pharmacotherapy
Drug advice provided in remote pharmacy services should be improved
A Finnish study: Safeguarding efficient antibacterial therapy calls for quick measures
Fimea develops services starting from the medical device operator and device register
Fimea’s customer satisfaction improved
Regulation of veterinary medicines also safeguards human health
Personnel training emphasises the sense of community
Fimea’s premises in Kuopio moved to Lake Kallavesi
Annual report 2021
Open submenu
, Annual report 2021
Fimea’s Year 2021
Open submenu
, Fimea’s Year 2021
COVID-19 continued to generate work
Enabling joint discussion and good interaction are important lessons learned for the period 2022-2023
Economy 2021
Open submenu
, Economy 2021
Structure of Fimea's funding 2021
Statistics 2021
Open submenu
, Statistics 2021
Shortage notifications 2016–2021
Inspections by control area 2017–2021
Marketing authorisation services in 2021
Number of marketing authorisations (marketing authorisations valid) 2017–2021
Pharmaceutical information 2021
Open submenu
, Pharmaceutical information 2021
Examination of the medicines data repository continued
Getting to know the Safe Pharmacotherapy Guide that promotes medication safety
Responsibility 2021
Open submenu
, Responsibility 2021
Responsibility at Fimea – Responsibility report 2021
Open submenu
, Responsibility at Fimea – Responsibility report 2021
Sustainable well-being through safe and effective medicines and medicinal products
Sustainable well-being and economy through rational use of medicines
Functional distribution of medicines
Impactful supervision
Fimea in brief 2021
Open submenu
, Fimea in brief 2021
Fimea’s strategy journey continued with the restructuring of its organisation
Meds75+ promotes medication safety in older people - the goal is international recognition
Annual report 2020
Open submenu
, Annual report 2020
Fimea's Year 2020
Open submenu
, Fimea's Year 2020
Travel restrictions speeded up the adoption of remote inspections
Fimea is strongly involved in the management of the corona epidemic
Economy 2020
Open submenu
, Economy 2020
Structure of Fimea's funding 2020
Statistics 2020
Open submenu
, Statistics 2020
Number of marketing authorisations (marketing authorisations valid) 2016–2020
Inspections by control area 2016-2020
Shortage notifications 2015–2020
Marketing authorisation services in 2020
Pharmaceutical information 2020
Open submenu
, Pharmaceutical information 2020
The use of the Meds75+ database in healthcare improves the medication safety of the elderly
Responsibility 2020
Open submenu
, Responsibility 2020
Accessible to all
Fimea in brief 2020
Open submenu
, Fimea in brief 2020
Sustainable wellbeing through safe medicines and medicinal products, combined with effective service
Fimea Sustainability Report 2022
Open submenu
, Fimea Sustainability Report 2022
Director General’s review and Fimea’s sustainability policies
Meeting the demand for medicines and medical products
Safe medicinal treatment of production animals, environmental protection and reduction of national drug wastage
Case example: Development of an antimicrobial consumption application
Supporting innovation and developing infrastructure
Safety of medicines and the production of reliable medicines information
Case example: Nitrosamine impurities in medicines challenge the authorities and industry
Fimea’s footprint – social, ecological and economic sustainability
Annual report 2023
Annual report 2022
Annual report 2021
Fimea’s Year 2021
Economy 2021
Statistics 2021
Shortage notifications 2016–2021
Inspections by control area 2017–2021
Marketing authorisation services in 2021
Number of marketing authorisations (marketing authorisations valid) 2017–2021
Pharmaceutical information 2021
Responsibility 2021
Fimea in brief 2021
Annual report 2020
Fimea Sustainability Report 2022
Valitse kieli
Suomi
Välj språket
Svenska
Select language
English
Shortage notifications 2016–2021
Hidden